_id
691b15ec3c536f8df2318b94
Ticker
IPN.PA
Name
Ipsen SA
Exchange
PA
Address
70 rue Balard, Paris, France, 75015
Country
France
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
EUR
Website
https://www.ipsen.com
Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Last Close
119
Volume
28760
Current Price
127.8
Change
0.3372681281618935
Last Updated
2025-12-31T15:55:58.042Z
Image
https://logo.clearbit.com/www.ipsen.com
Ipo Date
2005-12-07T00:00:00.000Z
Market Cap
9814497280
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
3.43
Strong Buy
2
Buy
4
Hold
7
Sell
0
Strong Sell
1
Current Quarter
2025-06-30
Revenue
1819800000
Cost Of Revenue
325100000
Gross Profit
1494700000
Operating Expenses
854200000
Operating Income
640500000
Interest Expense
15700000
Pretax Income
425000000
Net Income
334000000
Eps
4
Dividends Per Share
116200000
Shares Outstanding
82402087
Income Tax Expense
89500000
EBITDA
637000000
Operating Margin
35.19617540389054
Total Other Income Expense Net
-215500000
Cash
1445000000
Short Term Investments
32300000
Receivables
958000000
Inventories
269400000
Total Current Assets
2814100000
Property Plant Equipment
665300000
Total Assets
6830500000
Payables
852000000
Short Term Debt
123700000
Long Term Debt
745600000
Total Liabilities
2600000000
Equity
4229100000
Bs_currency_symbol
EUR
Depreciation
195800000
Change In Working Capital
-32600000
Cash From Operations
526700000
Capital Expenditures
55300000
Cash From Investing
-132900000
Cash From Financing
354700000
Net Change In Cash
766900000
Cf_currency_symbol
EUR
PE
22.1601
PB
2.5233028303894445
ROE
7.897661440968527
ROA
4.889832369519069
FCF
471400000
Fcf Percent
0.25903945488515223
Piotroski FScore
4
Health Score
76
Deep Value Investing Score
5.5
Defensive Investing Score
6.5
Dividend Investing Score
3.5
Economic Moat Investing Score
8
Garp Investing Score
6
Growth Investing Score
5
Momentum Investing Score
6.5
Net Net Investing Score
2.5
Quality Investing Score
7.5
Value Investing Score
6
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
1819800000
Quarters > 0 > income Statement > cost Of Revenue
325100000
Quarters > 0 > income Statement > gross Profit
1494700000
Quarters > 0 > income Statement > operating Expenses
854200000
Quarters > 0 > income Statement > operating Income
640500000
Quarters > 0 > income Statement > interest Expense
15700000
Quarters > 0 > income Statement > pretax Income
425000000
Quarters > 0 > income Statement > net Income
334000000
Quarters > 0 > income Statement > eps
4
Quarters > 0 > income Statement > dividends Per Share
116200000
Quarters > 0 > income Statement > shares Outstanding
83500000
Quarters > 0 > income Statement > income Tax Expense
89500000
Quarters > 0 > income Statement > EBITDA
637000000
Quarters > 0 > income Statement > operating Margin
35.19617540389054
Quarters > 0 > income Statement > total Other Income Expense Net
-215500000
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
1445000000
Quarters > 0 > balance Sheet > short Term Investments
32300000
Quarters > 0 > balance Sheet > receivables
958000000
Quarters > 0 > balance Sheet > inventories
269400000
Quarters > 0 > balance Sheet > total Current Assets
2814100000
Quarters > 0 > balance Sheet > property Plant Equipment
665300000
Quarters > 0 > balance Sheet > total Assets
6830500000
Quarters > 0 > balance Sheet > payables
852000000
Quarters > 0 > balance Sheet > short Term Debt
123700000
Quarters > 0 > balance Sheet > long Term Debt
745600000
Quarters > 0 > balance Sheet > total Liabilities
2600000000
Quarters > 0 > balance Sheet > equity
4229100000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
334000000
Quarters > 0 > cash Flow > depreciation
195800000
Quarters > 0 > cash Flow > change In Working Capital
-32600000
Quarters > 0 > cash Flow > cash From Operations
526700000
Quarters > 0 > cash Flow > capital Expenditures
55300000
Quarters > 0 > cash Flow > cash From Investing
-132900000
Quarters > 0 > cash Flow > cash From Financing
354700000
Quarters > 0 > cash Flow > net Change In Cash
766900000
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
4
Quarters > 0 > ratios > PB
2.5233028303894445
Quarters > 0 > ratios > ROE
7.897661440968527
Quarters > 0 > ratios > ROA
4.889832369519069
Quarters > 0 > ratios > FCF
471400000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.25903945488515223
Quarters > 0 > health Score
76
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
1822700000
Quarters > 1 > income Statement > cost Of Revenue
302000000
Quarters > 1 > income Statement > gross Profit
1520700000
Quarters > 1 > income Statement > operating Expenses
1341800000
Quarters > 1 > income Statement > operating Income
178900000
Quarters > 1 > income Statement > interest Expense
12200000
Quarters > 1 > income Statement > pretax Income
142700000
Quarters > 1 > income Statement > net Income
113900000
Quarters > 1 > income Statement > eps
1.3678951149427012
Quarters > 1 > income Statement > dividends Per Share
300000
Quarters > 1 > income Statement > shares Outstanding
83266618
Quarters > 1 > income Statement > income Tax Expense
27700000
Quarters > 1 > income Statement > EBITDA
709800000
Quarters > 1 > income Statement > operating Margin
9.81510945300927
Quarters > 1 > income Statement > total Other Income Expense Net
-36200000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
678100000
Quarters > 1 > balance Sheet > short Term Investments
1100000
Quarters > 1 > balance Sheet > receivables
697200000
Quarters > 1 > balance Sheet > inventories
285500000
Quarters > 1 > balance Sheet > total Current Assets
2021200000
Quarters > 1 > balance Sheet > property Plant Equipment
664200000
Quarters > 1 > balance Sheet > total Assets
6439000000
Quarters > 1 > balance Sheet > payables
854800000
Quarters > 1 > balance Sheet > short Term Debt
122900000
Quarters > 1 > balance Sheet > long Term Debt
287500000
Quarters > 1 > balance Sheet > total Liabilities
2257200000
Quarters > 1 > balance Sheet > equity
4181600000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
113900000
Quarters > 1 > cash Flow > depreciation
221000000
Quarters > 1 > cash Flow > change In Working Capital
20800000
Quarters > 1 > cash Flow > cash From Operations
446300000
Quarters > 1 > cash Flow > capital Expenditures
113700000
Quarters > 1 > cash Flow > cash From Investing
-477500000
Quarters > 1 > cash Flow > cash From Financing
221400000
Quarters > 1 > cash Flow > net Change In Cash
192700000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
1.3678951149427012
Quarters > 1 > ratios > PB
2.5448330257317773
Quarters > 1 > ratios > ROE
2.723837765448632
Quarters > 1 > ratios > ROA
1.7689082155614224
Quarters > 1 > ratios > FCF
332600000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.18247654578372743
Quarters > 1 > health Score
68
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
1751800000
Quarters > 2 > income Statement > cost Of Revenue
316700000
Quarters > 2 > income Statement > gross Profit
1435100000
Quarters > 2 > income Statement > operating Expenses
1117300000
Quarters > 2 > income Statement > operating Income
317800000
Quarters > 2 > income Statement > interest Expense
10900000
Quarters > 2 > income Statement > pretax Income
289500000
Quarters > 2 > income Statement > net Income
232000000
Quarters > 2 > income Statement > eps
2.780000013660345
Quarters > 2 > income Statement > dividends Per Share
99800000
Quarters > 2 > income Statement > shares Outstanding
83453237
Quarters > 2 > income Statement > income Tax Expense
47200000
Quarters > 2 > income Statement > EBITDA
481700000
Quarters > 2 > income Statement > operating Margin
18.141340335654753
Quarters > 2 > income Statement > total Other Income Expense Net
-28300000
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
485400000
Quarters > 2 > balance Sheet > short Term Investments
8100000
Quarters > 2 > balance Sheet > receivables
719200000
Quarters > 2 > balance Sheet > inventories
272700000
Quarters > 2 > balance Sheet > total Current Assets
1899800000
Quarters > 2 > balance Sheet > property Plant Equipment
594200000
Quarters > 2 > balance Sheet > total Assets
6547200000
Quarters > 2 > balance Sheet > payables
857600000
Quarters > 2 > balance Sheet > short Term Debt
135100000
Quarters > 2 > balance Sheet > long Term Debt
280400000
Quarters > 2 > balance Sheet > total Liabilities
2501100000
Quarters > 2 > balance Sheet > equity
4046900000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
232000000
Quarters > 2 > cash Flow > depreciation
185000000
Quarters > 2 > cash Flow > change In Working Capital
-134100000
Quarters > 2 > cash Flow > cash From Operations
466000000
Quarters > 2 > cash Flow > capital Expenditures
59300000
Quarters > 2 > cash Flow > cash From Investing
-199100000
Quarters > 2 > cash Flow > cash From Financing
-318200000
Quarters > 2 > cash Flow > net Change In Cash
467500000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
2.780000013660345
Quarters > 2 > ratios > PB
2.63543049954286
Quarters > 2 > ratios > ROE
5.7327831179421285
Quarters > 2 > ratios > ROA
3.543499511241447
Quarters > 2 > ratios > FCF
406700000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.23216120561707956
Quarters > 2 > health Score
73
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
1590900000
Quarters > 3 > income Statement > cost Of Revenue
301300000
Quarters > 3 > income Statement > gross Profit
1289600000
Quarters > 3 > income Statement > operating Expenses
818900000
Quarters > 3 > income Statement > operating Income
470700000
Quarters > 3 > income Statement > interest Expense
11200000
Quarters > 3 > income Statement > pretax Income
500100000
Quarters > 3 > income Statement > net Income
449200000
Quarters > 3 > income Statement > eps
5.378915885490496
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
83511252
Quarters > 3 > income Statement > income Tax Expense
80200000
Quarters > 3 > income Statement > EBITDA
671900000
Quarters > 3 > income Statement > operating Margin
29.587026211578355
Quarters > 3 > income Statement > total Other Income Expense Net
29400000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
528400000
Quarters > 3 > balance Sheet > short Term Investments
10600000
Quarters > 3 > balance Sheet > receivables
686500000
Quarters > 3 > balance Sheet > inventories
289500000
Quarters > 3 > balance Sheet > total Current Assets
1898400000
Quarters > 3 > balance Sheet > property Plant Equipment
574600000
Quarters > 3 > balance Sheet > total Assets
6322900000
Quarters > 3 > balance Sheet > payables
771400000
Quarters > 3 > balance Sheet > short Term Debt
36400000
Quarters > 3 > balance Sheet > long Term Debt
269700000
Quarters > 3 > balance Sheet > total Liabilities
2499000000
Quarters > 3 > balance Sheet > equity
3825100000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
449200000
Quarters > 3 > cash Flow > depreciation
189500000
Quarters > 3 > cash Flow > change In Working Capital
45600000
Quarters > 3 > cash Flow > cash From Operations
436500000
Quarters > 3 > cash Flow > capital Expenditures
75600000
Quarters > 3 > cash Flow > cash From Investing
-86200000
Quarters > 3 > cash Flow > cash From Financing
-248300000
Quarters > 3 > cash Flow > net Change In Cash
115000000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
5.378915885490496
Quarters > 3 > ratios > PB
2.7901853560952654
Quarters > 3 > ratios > ROE
11.743483830488092
Quarters > 3 > ratios > ROA
7.1043350361384805
Quarters > 3 > ratios > FCF
360900000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
0.22685272487271355
Quarters > 3 > health Score
80
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
3574500000
Annuals > 0 > income Statement > cost Of Revenue
618700000
Annuals > 0 > income Statement > gross Profit
2955800000
Annuals > 0 > income Statement > operating Expenses
2459100000
Annuals > 0 > income Statement > operating Income
496700000
Annuals > 0 > income Statement > interest Expense
23800000
Annuals > 0 > income Statement > pretax Income
432200000
Annuals > 0 > income Statement > net Income
345900000
Annuals > 0 > income Statement > eps
4.147895112911365
Annuals > 0 > income Statement > dividends Per Share
99600000
Annuals > 0 > income Statement > shares Outstanding
83391694
Annuals > 0 > income Statement > income Tax Expense
74900000
Annuals > 0 > income Statement > EBITDA
1161300000
Annuals > 0 > income Statement > operating Margin
13.895649741222549
Annuals > 0 > income Statement > total Other Income Expense Net
-64500000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
678100000
Annuals > 0 > balance Sheet > short Term Investments
1100000
Annuals > 0 > balance Sheet > receivables
697200000
Annuals > 0 > balance Sheet > inventories
285500000
Annuals > 0 > balance Sheet > total Current Assets
2021200000
Annuals > 0 > balance Sheet > property Plant Equipment
664200000
Annuals > 0 > balance Sheet > total Assets
6439000000
Annuals > 0 > balance Sheet > payables
854800000
Annuals > 0 > balance Sheet > short Term Debt
37200000
Annuals > 0 > balance Sheet > long Term Debt
287500000
Annuals > 0 > balance Sheet > total Liabilities
2257200000
Annuals > 0 > balance Sheet > equity
4181600000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
345900000
Annuals > 0 > cash Flow > depreciation
705900000
Annuals > 0 > cash Flow > change In Working Capital
-54500000
Annuals > 0 > cash Flow > cash From Operations
915500000
Annuals > 0 > cash Flow > capital Expenditures
782500000
Annuals > 0 > cash Flow > cash From Investing
-676600000
Annuals > 0 > cash Flow > cash From Financing
-100000000
Annuals > 0 > cash Flow > net Change In Cash
158100000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
4.147895112911365
Annuals > 0 > ratios > PB
2.373161370288885
Annuals > 0 > ratios > ROE
8.271953319303616
Annuals > 0 > ratios > ROA
5.371952166485479
Annuals > 0 > ratios > FCF
133000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.037208001119037624
Annuals > 0 > health Score
61
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
3306400000
Annuals > 1 > income Statement > cost Of Revenue
571200000
Annuals > 1 > income Statement > gross Profit
2735200000
Annuals > 1 > income Statement > operating Expenses
1919200000
Annuals > 1 > income Statement > operating Income
816000000
Annuals > 1 > income Statement > interest Expense
19400000
Annuals > 1 > income Statement > pretax Income
756100000
Annuals > 1 > income Statement > net Income
644400000
Annuals > 1 > income Statement > eps
7.728915879698153
Annuals > 1 > income Statement > dividends Per Share
99600000
Annuals > 1 > income Statement > shares Outstanding
83375212
Annuals > 1 > income Statement > income Tax Expense
136200000
Annuals > 1 > income Statement > EBITDA
1143000000
Annuals > 1 > income Statement > operating Margin
24.679409629808855
Annuals > 1 > income Statement > total Other Income Expense Net
-59900000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
528400000
Annuals > 1 > balance Sheet > short Term Investments
10600000
Annuals > 1 > balance Sheet > receivables
631300000
Annuals > 1 > balance Sheet > inventories
289500000
Annuals > 1 > balance Sheet > total Current Assets
1898400000
Annuals > 1 > balance Sheet > property Plant Equipment
574600000
Annuals > 1 > balance Sheet > total Assets
6322900000
Annuals > 1 > balance Sheet > payables
771400000
Annuals > 1 > balance Sheet > short Term Debt
36400000
Annuals > 1 > balance Sheet > long Term Debt
269700000
Annuals > 1 > balance Sheet > total Liabilities
2499100000
Annuals > 1 > balance Sheet > equity
3825100000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
617100000
Annuals > 1 > cash Flow > depreciation
87900000
Annuals > 1 > cash Flow > change In Working Capital
76100000
Annuals > 1 > cash Flow > cash From Operations
865900000
Annuals > 1 > cash Flow > capital Expenditures
116200000
Annuals > 1 > cash Flow > cash From Investing
-1072200000
Annuals > 1 > cash Flow > cash From Financing
-458400000
Annuals > 1 > cash Flow > net Change In Cash
-646000000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
7.728915879698153
Annuals > 1 > ratios > PB
2.5938276719562885
Annuals > 1 > ratios > ROE
16.846618389061724
Annuals > 1 > ratios > ROA
10.191526040266334
Annuals > 1 > ratios > FCF
749700000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.22674207597386886
Annuals > 1 > health Score
88
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
3156400000
Annuals > 2 > income Statement > cost Of Revenue
527700000
Annuals > 2 > income Statement > gross Profit
2628700000
Annuals > 2 > income Statement > operating Expenses
1905800000
Annuals > 2 > income Statement > operating Income
943700000
Annuals > 2 > income Statement > interest Expense
23800000
Annuals > 2 > income Statement > pretax Income
704400000
Annuals > 2 > income Statement > net Income
648600000
Annuals > 2 > income Statement > eps
7.805256562309167
Annuals > 2 > income Statement > dividends Per Share
99300000
Annuals > 2 > income Statement > shares Outstanding
83097845
Annuals > 2 > income Statement > income Tax Expense
112300000
Annuals > 2 > income Statement > EBITDA
1130900000
Annuals > 2 > income Statement > operating Margin
29.897985046255226
Annuals > 2 > income Statement > total Other Income Expense Net
-25500000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
1169300000
Annuals > 2 > balance Sheet > short Term Investments
31000000
Annuals > 2 > balance Sheet > receivables
670800000
Annuals > 2 > balance Sheet > inventories
284100000
Annuals > 2 > balance Sheet > total Current Assets
2397600000
Annuals > 2 > balance Sheet > property Plant Equipment
581400000
Annuals > 2 > balance Sheet > total Assets
5607900000
Annuals > 2 > balance Sheet > payables
647100000
Annuals > 2 > balance Sheet > short Term Debt
104600000
Annuals > 2 > balance Sheet > long Term Debt
667000000
Annuals > 2 > balance Sheet > total Liabilities
2271200000
Annuals > 2 > balance Sheet > equity
3337300000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
592100000
Annuals > 2 > cash Flow > depreciation
336500000
Annuals > 2 > cash Flow > change In Working Capital
-39100000
Annuals > 2 > cash Flow > cash From Operations
971400000
Annuals > 2 > cash Flow > capital Expenditures
252900000
Annuals > 2 > cash Flow > cash From Investing
-458600000
Annuals > 2 > cash Flow > cash From Financing
-164200000
Annuals > 2 > cash Flow > net Change In Cash
356400000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
7.805256562309167
Annuals > 2 > ratios > PB
2.9630670167500672
Annuals > 2 > ratios > ROE
19.43487250172295
Annuals > 2 > ratios > ROA
11.565826780078105
Annuals > 2 > ratios > FCF
718500000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.22763274616651882
Annuals > 2 > health Score
90
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
2748600000
Annuals > 3 > income Statement > cost Of Revenue
438600000
Annuals > 3 > income Statement > gross Profit
2310000000
Annuals > 3 > income Statement > operating Expenses
1498700000
Annuals > 3 > income Statement > operating Income
886200000
Annuals > 3 > income Statement > interest Expense
23700000
Annuals > 3 > income Statement > pretax Income
789500000
Annuals > 3 > income Statement > net Income
646600000
Annuals > 3 > income Statement > eps
7.7568643150723595
Annuals > 3 > income Statement > dividends Per Share
82900000
Annuals > 3 > income Statement > shares Outstanding
83358426
Annuals > 3 > income Statement > income Tax Expense
158300000
Annuals > 3 > income Statement > EBITDA
1059200000
Annuals > 3 > income Statement > operating Margin
32.24186858764462
Annuals > 3 > income Statement > total Other Income Expense Net
-35200000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
814700000
Annuals > 3 > balance Sheet > short Term Investments
42400000
Annuals > 3 > balance Sheet > receivables
787900000
Annuals > 3 > balance Sheet > inventories
219400000
Annuals > 3 > balance Sheet > total Current Assets
1953800000
Annuals > 3 > balance Sheet > property Plant Equipment
647500000
Annuals > 3 > balance Sheet > total Assets
4990500000
Annuals > 3 > balance Sheet > payables
594700000
Annuals > 3 > balance Sheet > short Term Debt
123700000
Annuals > 3 > balance Sheet > long Term Debt
772200000
Annuals > 3 > balance Sheet > total Liabilities
2252800000
Annuals > 3 > balance Sheet > equity
2735200000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
646700000
Annuals > 3 > cash Flow > depreciation
237000000
Annuals > 3 > cash Flow > change In Working Capital
-32200000
Annuals > 3 > cash Flow > cash From Operations
909200000
Annuals > 3 > cash Flow > capital Expenditures
427700000
Annuals > 3 > cash Flow > cash From Investing
-344200000
Annuals > 3 > cash Flow > cash From Financing
-401200000
Annuals > 3 > cash Flow > net Change In Cash
169500000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
7.7568643150723595
Annuals > 3 > ratios > PB
3.626664483035975
Annuals > 3 > ratios > ROE
23.639953202690844
Annuals > 3 > ratios > ROA
12.95661757338944
Annuals > 3 > ratios > FCF
481500000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.17518009168303864
Annuals > 3 > health Score
83
Valuation > metrics > PE
22.1601
Valuation > metrics > PB
2.5233028303894445
Valuation > final Score
100
Valuation > verdict
Fair
Profitability > metrics > ROE
7.897661440968527
Profitability > metrics > ROA
11.868803525105717
Profitability > metrics > Net Margin
0.18353665237938235
Profitability > final Score
73
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.6147880163628195
Risk > metrics > Interest Coverage
40.796178343949045
Risk > final Score
88
Risk > verdict
Low
Liquidity > metrics > Current Ratio
2.884185712821564
Liquidity > metrics > Quick Ratio
2.6080762529466024
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
32
Prev Profitabilities > 1
61
Prev Profitabilities > 2
83
Prev Risks > 0
88
Prev Risks > 1
88
Prev Risks > 2
88
Prev Liquidities > 0
100
Prev Liquidities > 1
98
Prev Liquidities > 2
100
Updated At
2026-01-20T23:10:06.880Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-12
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-10-22
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-07-31
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
4
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-04-16
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
1.37
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
1.37
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-13
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
1.37
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
1.37
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-10-23
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-07-25
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-04-24
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-08
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
5.23
Earnings History > 8 > eps Difference
-5.23
Earnings History > 8 > surprise Percent
-100
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-10-26
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-07-27
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
4.98
Earnings History > 10 > eps Estimate
4.67
Earnings History > 10 > eps Difference
0.31
Earnings History > 10 > surprise Percent
6.6381
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-04-27
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-02-09
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
2.14
Earnings History > 12 > eps Estimate
4.71
Earnings History > 12 > eps Difference
-2.57
Earnings History > 12 > surprise Percent
-54.5648
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-10-26
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
0
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-07-28
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
4.59
Earnings History > 14 > eps Estimate
4.87
Earnings History > 14 > eps Difference
-0.28
Earnings History > 14 > surprise Percent
-5.7495
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-04-27
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
0
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-02-11
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
EUR
Earnings History > 16 > eps Actual
7.76
Earnings History > 16 > eps Estimate
3.39
Earnings History > 16 > eps Difference
4.37
Earnings History > 16 > surprise Percent
128.9086
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-10-21
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
EUR
Earnings History > 17 > eps Actual
0
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-07-29
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
EUR
Earnings History > 18 > eps Actual
3.63
Earnings History > 18 > eps Estimate
3.75
Earnings History > 18 > eps Difference
-0.12
Earnings History > 18 > surprise Percent
-3.2
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-04-22
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
EUR
Earnings History > 19 > eps Actual
0
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-02-11
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
EUR
Earnings History > 20 > eps Actual
6.52
Earnings History > 20 > eps Estimate
3.8
Earnings History > 20 > eps Difference
2.72
Earnings History > 20 > surprise Percent
71.5789
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-10-22
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
EUR
Earnings History > 21 > eps Actual
0
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-07-30
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
EUR
Earnings History > 22 > eps Actual
2.66
Earnings History > 22 > eps Estimate
3.48
Earnings History > 22 > eps Difference
-0.82
Earnings History > 22 > surprise Percent
-23.5632
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-04-22
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
EUR
Earnings History > 23 > eps Actual
0
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
0
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-02-13
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
EUR
Earnings History > 24 > eps Actual
-3.26
Earnings History > 24 > eps Estimate
3.46
Earnings History > 24 > eps Difference
-6.72
Earnings History > 24 > surprise Percent
-194.2197
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-10-24
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
EUR
Earnings History > 25 > eps Actual
0
Earnings History > 25 > eps Estimate
0
Earnings History > 25 > eps Difference
0
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-07-25
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
EUR
Earnings History > 26 > eps Actual
2.59
Earnings History > 26 > eps Estimate
3.64
Earnings History > 26 > eps Difference
-1.05
Earnings History > 26 > surprise Percent
-28.8462
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-04-24
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
EUR
Earnings History > 27 > eps Actual
0
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2018-12-31
Earnings History > 28 > report Date
2019-02-14
Earnings History > 28 > date
2018-12-31
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
EUR
Earnings History > 28 > eps Actual
2.28
Earnings History > 28 > eps Estimate
3.08
Earnings History > 28 > eps Difference
-0.8
Earnings History > 28 > surprise Percent
-25.974
Earnings History > 29 > period
2018-09-30
Earnings History > 29 > report Date
2018-10-25
Earnings History > 29 > date
2018-09-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
EUR
Earnings History > 29 > eps Actual
0
Earnings History > 29 > eps Estimate
0
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2018-06-30
Earnings History > 30 > report Date
2018-07-26
Earnings History > 30 > date
2018-06-30
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
EUR
Earnings History > 30 > eps Actual
2.86
Earnings History > 30 > eps Estimate
2.84
Earnings History > 30 > eps Difference
0.02
Earnings History > 30 > surprise Percent
0.7042
Earnings History > 31 > period
2018-03-31
Earnings History > 31 > report Date
2018-04-26
Earnings History > 31 > date
2018-03-31
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
EUR
Earnings History > 31 > eps Actual
0
Earnings History > 31 > eps Estimate
2.77
Earnings History > 31 > eps Difference
-2.77
Earnings History > 31 > surprise Percent
-100
Earnings History > 32 > period
2017-12-31
Earnings History > 32 > report Date
2018-02-15
Earnings History > 32 > date
2017-12-31
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
EUR
Earnings History > 32 > eps Actual
1.77
Earnings History > 32 > eps Estimate
1.92
Earnings History > 32 > eps Difference
-0.15
Earnings History > 32 > surprise Percent
-7.8125
Earnings History > 33 > period
2017-09-30
Earnings History > 33 > report Date
2017-10-26
Earnings History > 33 > date
2017-09-30
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
EUR
Earnings History > 33 > eps Actual
0
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
0
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2017-06-30
Earnings History > 34 > report Date
2017-07-27
Earnings History > 34 > date
2017-06-30
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
EUR
Earnings History > 34 > eps Actual
1.48
Earnings History > 34 > eps Estimate
1.82
Earnings History > 34 > eps Difference
-0.34
Earnings History > 34 > surprise Percent
-18.6813
Earnings History > 35 > period
2017-03-31
Earnings History > 35 > report Date
2017-04-27
Earnings History > 35 > date
2017-03-31
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
EUR
Earnings History > 35 > eps Actual
0
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
0
Earnings History > 35 > surprise Percent
-
Earnings History > 36 > period
2016-12-31
Earnings History > 36 > report Date
2017-02-27
Earnings History > 36 > date
2016-12-31
Earnings History > 36 > before After Market
-
Earnings History > 36 > currency
EUR
Earnings History > 36 > eps Actual
0
Earnings History > 36 > eps Estimate
1.42
Earnings History > 36 > eps Difference
-1.42
Earnings History > 36 > surprise Percent
-100
Earnings History > 37 > period
2016-09-30
Earnings History > 37 > report Date
2016-10-26
Earnings History > 37 > date
2016-09-30
Earnings History > 37 > before After Market
-
Earnings History > 37 > currency
EUR
Earnings History > 37 > eps Actual
0
Earnings History > 37 > eps Estimate
0
Earnings History > 37 > eps Difference
0
Earnings History > 37 > surprise Percent
-
Earnings History > 38 > period
2016-06-30
Earnings History > 38 > report Date
2016-07-28
Earnings History > 38 > date
2016-06-30
Earnings History > 38 > before After Market
-
Earnings History > 38 > currency
EUR
Earnings History > 38 > eps Actual
0
Earnings History > 38 > eps Estimate
1.55
Earnings History > 38 > eps Difference
-1.55
Earnings History > 38 > surprise Percent
-100
Earnings History > 39 > period
2015-12-31
Earnings History > 39 > report Date
2016-03-01
Earnings History > 39 > date
2015-12-31
Earnings History > 39 > before After Market
-
Earnings History > 39 > currency
EUR
Earnings History > 39 > eps Actual
0
Earnings History > 39 > eps Estimate
1.35
Earnings History > 39 > eps Difference
-1.35
Earnings History > 39 > surprise Percent
-100
Earnings History > 40 > period
2015-06-30
Earnings History > 40 > report Date
2015-07-31
Earnings History > 40 > date
2015-06-30
Earnings History > 40 > before After Market
-
Earnings History > 40 > currency
EUR
Earnings History > 40 > eps Actual
0
Earnings History > 40 > eps Estimate
1.52
Earnings History > 40 > eps Difference
-1.52
Earnings History > 40 > surprise Percent
-100
Earnings History > 41 > period
2014-12-31
Earnings History > 41 > report Date
2015-03-03
Earnings History > 41 > date
2014-12-31
Earnings History > 41 > before After Market
-
Earnings History > 41 > currency
EUR
Earnings History > 41 > eps Actual
0
Earnings History > 41 > eps Estimate
0
Earnings History > 41 > eps Difference
0
Earnings History > 41 > surprise Percent
-
Earnings History > 42 > period
2014-06-30
Earnings History > 42 > report Date
2014-08-29
Earnings History > 42 > date
2014-06-30
Earnings History > 42 > before After Market
-
Earnings History > 42 > currency
EUR
Earnings History > 42 > eps Actual
0
Earnings History > 42 > eps Estimate
1.14
Earnings History > 42 > eps Difference
-1.14
Earnings History > 42 > surprise Percent
-100
Earnings History > 43 > period
2013-12-31
Earnings History > 43 > report Date
2014-02-28
Earnings History > 43 > date
2013-12-31
Earnings History > 43 > before After Market
-
Earnings History > 43 > currency
EUR
Earnings History > 43 > eps Actual
0
Earnings History > 43 > eps Estimate
0.67
Earnings History > 43 > eps Difference
-0.67
Earnings History > 43 > surprise Percent
-100
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIs Ipsen (ENXTPA:IPN) Pricing Fair After Strong Multi Year Share Price Gains - Yahoo Finance
1/14/2026
Is Ipsen (ENXTPA:IPN) Pricing Fair After Strong Multi Year Share Price Gains Yahoo Finance
Read more →Ipsen (ENXTPA:IPN): Assessing Valuation After Recent Share Price Momentum Yahoo Finance
Read more →Showing 2 of 4
(Last Updated 2025-06-30)
Rating:
HOLD
$
Analyst Picks
Strong Buy
2
Buy
4
Hold
7
Sell
0
Strong Sell
1
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Ipsen SA
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-09-30
EPS Actual
0
EPS Estimate
0
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.